InspireMD, Inc. (NSPR)

NASDAQ: NSPR · IEX Real-Time Price · USD
2.400
0.00 (0.00%)
Jul 22, 2024, 12:05 PM EDT - Market open
0.00%
Market Cap 60.15M
Revenue (ttm) 6.48M
Net Income (ttm) -22.69M
Shares Out 24.96M
EPS (ttm) -0.73
PE Ratio n/a
Forward PE 11.70
Dividend n/a
Ex-Dividend Date n/a
Volume 816
Open 2.410
Previous Close 2.400
Day's Range 2.400 - 2.410
52-Week Range 1.810 - 3.850
Beta 0.97
Analysts Buy
Price Target 4.50 (+87.5%)
Earnings Date Aug 6, 2024

About NSPR

InspireMD, Inc., a medical device company, focuses on the development and commercialization of MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Stent System, a mesh-covered self-expanding carotid stent; and SwitchGuard NPS, a non-invasive transcarotid artery revascularization device; as well as treating acute stroke with tandem le... [Read more]

Industry Medical Devices
Sector Healthcare
CEO Marvin L. Slosman
Employees 66
Stock Exchange NASDAQ
Ticker Symbol NSPR
Full Company Profile

Financial Performance

In 2023, InspireMD's revenue was $6.21 million, an increase of 20.00% compared to the previous year's $5.17 million. Losses were -$19.92 million, 7.71% more than in 2022.

Financial Statements

Analyst Forecast

According to one analyst, the rating for NSPR stock is "Buy" and the 12-month stock price forecast is $4.5.

Price Target
$4.5
(87.50% upside)
Analyst Consensus: Buy
Stock Forecasts

News

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

Data demonstrate lowest reported primary endpoint event rate of 1.95% through twelve months post-procedure for any carotid stent or embolic protection device pivotal trial

7 weeks ago - GlobeNewsWire

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

- Generated first quarter 2024 CGuard EPS revenue of $1.51 million, an increase of 22.0% over the first quarter of 2023 -

2 months ago - GlobeNewsWire

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

TEL AVIV, Israel and MIAMI, May 07, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery D...

2 months ago - GlobeNewsWire

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

TEL AVIV, Israel and MIAMI, April 03, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announ...

3 months ago - GlobeNewsWire

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

TEL AVIV, Israel and MIAMI, March 26, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announ...

4 months ago - GlobeNewsWire

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

- Record fourth quarter 2023 CGuard EPS revenue of $1.76 million increased 71.6% over fourth quarter 2022 - - Announced positive 30-day data from the Company's ongoing U.S. Investigational Device Exem...

4 months ago - GlobeNewsWire

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Feb. 28, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Sten...

5 months ago - GlobeNewsWire

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

Development of SwitchGuard™ consistent with Company's mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class caro...

5 months ago - GlobeNewsWire

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

TEL AVIV, Israel and MIAMI, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Carotid Stent System (EPS) for the prevention of stroke, today...

6 months ago - GlobeNewsWire

InspireMD Announces Appointment of Medical Technology Executive Pete Ligotti as Executive Vice President and General Manager of North America

Appointment brings more than 30 years of medical technology general management and commercial leadership experience to the InspireMD team

7 months ago - GlobeNewsWire

InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection System

Reflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the preven...

7 months ago - GlobeNewsWire

InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem Lesions

TEL AVIV, Israel and MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announc...

8 months ago - GlobeNewsWire

InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update

- Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrating an overall major adverse events rate (DSMI) of 0.95% from pr...

9 months ago - GlobeNewsWire

InspireMD to Participate in Upcoming November Investor Conferences

TEL AVIV, Israel and MIAMI, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disea...

9 months ago - GlobeNewsWire

InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23

Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedure

9 months ago - GlobeNewsWire

InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th

-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Oct. 30, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Sten...

9 months ago - GlobeNewsWire

InspireMD Supports CMS' Final National Coverage Determination (NCD) Expanding Coverage of Carotid Stenting (CAS) to Include Both Asymptomatic and Standard Risk Patients

Provides additional treatment options for patients and treating physicians; likely expands CAS addressable market Potentially accelerates conversion of carotid interventions from surgery (carotid enda...

10 months ago - GlobeNewsWire

InspireMD Announces Senior Leadership Changes to Support Commercial Growth Initiatives

Announces hiring of Patrick Verta, MD, as Executive VP of Clinical and Medical Affairs Cheryl Tal joins as VP of Quality Assurance and Regulatory Affairs Shane Gleason, current General Manager of Nort...

10 months ago - GlobeNewsWire

InspireMD Announces Abstract of 30-Day Results from the C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at VIVA23

TEL AVIV, Israel, and MIAMI, Aug. 31, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announ...

11 months ago - GlobeNewsWire

InspireMD Reports Second Quarter 2023 Financial Results and Provides Business Update

- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront – - Completed enrollment in the C-Guardians US IDE trial; on track to announce primary and seco...

1 year ago - GlobeNewsWire

InspireMD to Report Second Quarter 2023 Financial Results and Provide Corporate Business Update on Tuesday, August 8th

-Conference call and webcast to be held at 8:30 a.m. EDT- TEL AVIV, Israel and MIAMI, July 25, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Sten...

1 year ago - GlobeNewsWire

InspireMD Announces Completion of Enrollment in C-Guardians U.S. Investigational Device Exemption (IDE) Clinical Trial

Trial designed to support potential U.S. marketing approval of the CGuard™ Prime EPS stent system Study also included first-in-human cases treated with CGuard Prime CAS stent delivery platform Company...

1 year ago - GlobeNewsWire

InspireMD Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

TEL AVIV, Israel and MIAMI, May 18, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announce...

1 year ago - GlobeNewsWire

InspireMD Reports First Quarter 2023 Financial Results and Provides Business Update

- Completed transformational private placement for up to $113.6 million, including $42.2 million upfront -

1 year ago - GlobeNewsWire

InspireMD Announces Private Placement of Up to $113.6 Million

Led by Marshall Wace with participation from OrbiMed, Rosalind, Nantahala, Soleus, Velan and certain InspireMD Board members

1 year ago - GlobeNewsWire